$26.99 0.8%
IDYA Stock Price vs. AI Score
Data gathered: November 27

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Ideaya Biosciences

IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.


Ideaya Biosciences
Price $26.99
Target Price Sign up
Volume 890,750
Market Cap $2.32B
Year Range $25.54 - $45.63
Dividend Yield 0%
Analyst Rating 94% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24010M-10M-52M-66M-0.600
Q2 '24011M-11M-53M-64M-0.680
Q1 '2408.8M-8.8M-40M-50M-0.530
Q4 '233.9M7.8M-3.8M-34M-41M-0.520
Q3 '238M8.5M-430,000-27M-33M-0.460

Insider Transactions View All

WHITE MICHAEL ANTHONY filed to sell 851 shares at $36.2.
May 31 '24
Hata Yujiro S filed to sell 677,887 shares at $42.4.
May 16 '24
Hata Yujiro S filed to sell 682,236 shares at $41.7.
May 16 '24
Hata Yujiro S filed to sell 677,887 shares at $44.1.
May 16 '24

What is the Market Cap of Ideaya Biosciences?

The Market Cap of Ideaya Biosciences is $2.32B.

What is the current stock price of Ideaya Biosciences?

Currently, the price of one share of Ideaya Biosciences stock is $26.99.

How can I analyze the IDYA stock price chart for investment decisions?

The IDYA stock price chart above provides a comprehensive visual representation of Ideaya Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ideaya Biosciences shares. Our platform offers an up-to-date IDYA stock price chart, along with technical data analysis and alternative data insights.

Does IDYA offer dividends to its shareholders?

As of our latest update, Ideaya Biosciences (IDYA) does not offer dividends to its shareholders. Investors interested in Ideaya Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Ideaya Biosciences?

Some of the similar stocks of Ideaya Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.